• Aliases: HM781-36B; NOV120101; pan-HER kinase inhibitor HM781-36B
    • A quinazoline-based, mall-molecular and irreversible inhibitor of EGFR (HER1 or ErbB1), ceritinib HER2, HER4, and EGFR mutants with exon 20 insertion.
    • Phase 2 ongoing clinical trial in EGFR–mutated advanced NSCLC, HER2-positive metastatic breast cancer patients who have received two prior lines of HER2 therapies, and in HER2-positive gastric cancer patients.
    • Recommended phase 2 dose: 12 to 16 mg PO daily for 14 days on, 7 days off in a fasted state.
    • Common side effects: Diarrhea, rash, fatigue, pruritus, stomatitis, and anorexia (Park    al., 2017)
    Other topics in Targeted and Immunotherapy Agents